These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28849629)

  • 1. Antialbuminuric effect of eplerenone in comparison to thiazide diuretics in patients with hypertension.
    Sawai T; Dohi K; Fujimoto N; Okubo S; Isaka N; Ichikawa T; Makino K; Okamoto S; Koyabu S; Kitamura T; Ogura T; Yamada T; Tamaru S; Nishikawa M; Nakamura M; Ito M;
    J Clin Hypertens (Greenwich); 2017 Oct; 19(10):990-998. PubMed ID: 28849629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
    Epstein M; Williams GH; Weinberger M; Lewin A; Krause S; Mukherjee R; Patni R; Beckerman B
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria.
    Ando K; Ohtsu H; Arakawa Y; Kubota K; Yamaguchi T; Nagase M; Yamada A; Fujita T;
    Hypertens Res; 2010 Jun; 33(6):616-21. PubMed ID: 20379190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
    Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T;
    Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses.
    Fernet M; Beckerman B; Abreu P; Lins K; Vincent J; Burgess E
    Vasc Health Risk Manag; 2018; 14():233-246. PubMed ID: 30275698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineralocorticoid receptor blockade suppresses dietary salt-induced ACEI/ARB-resistant albuminuria in non-diabetic hypertension: a sub-analysis of evaluate study.
    Nishimoto M; Ohtsu H; Marumo T; Kawarazaki W; Ayuzawa N; Ueda K; Hirohama D; Kawakami-Mori F; Shibata S; Nagase M; Isshiki M; Oba S; Shimosawa T; Fujita T
    Hypertens Res; 2019 Apr; 42(4):514-521. PubMed ID: 30631161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
    White WB; Duprez D; St Hillaire R; Krause S; Roniker B; Kuse-Hamilton J; Weber MA
    Hypertension; 2003 May; 41(5):1021-6. PubMed ID: 12682082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension.
    Musini VM; Nazer M; Bassett K; Wright JM
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD003824. PubMed ID: 24869750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension.
    Sato A; Fukuda S
    J Hum Hypertens; 2010 Jun; 24(6):387-94. PubMed ID: 19865106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension.
    Williams GH; Burgess E; Kolloch RE; Ruilope LM; Niegowska J; Kipnes MS; Roniker B; Patrick JL; Krause SL
    Am J Cardiol; 2004 Apr; 93(8):990-6. PubMed ID: 15081441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease.
    Pisoni R; Acelajado MC; Cartmill FR; Dudenbostel T; Dell'Italia LJ; Cofield SS; Oparil S; Calhoun DA
    J Hum Hypertens; 2012 Aug; 26(8):502-6. PubMed ID: 21677673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
    Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
    Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
    Pitt B; Reichek N; Willenbrock R; Zannad F; Phillips RA; Roniker B; Kleiman J; Krause S; Burns D; Williams GH
    Circulation; 2003 Oct; 108(15):1831-8. PubMed ID: 14517164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.
    Du J; Fan YY; Hitomi H; Kiyomoto H; Kimura S; Kong CZ; Noma T; Kohno M; Nishiyama A; Nakano D
    Am J Physiol Renal Physiol; 2009 Sep; 297(3):F802-8. PubMed ID: 19535572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension.
    Burgess ED; Lacourcière Y; Ruilope-Urioste LM; Oparil S; Kleiman JH; Krause S; Roniker B; Maurath C
    Clin Ther; 2003 Sep; 25(9):2388-404. PubMed ID: 14604739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.
    Weinberger MH; Roniker B; Krause SL; Weiss RJ
    Am J Hypertens; 2002 Aug; 15(8):709-16. PubMed ID: 12160194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low dose-eplerenone treatment decreases aortic stiffness in patients with resistant hypertension.
    Kalizki T; Schmidt BMW; Raff U; Reinold A; Schwarz TK; Schneider MP; Schmieder RE; Schneider A
    J Clin Hypertens (Greenwich); 2017 Jul; 19(7):669-676. PubMed ID: 28211216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension.
    White WB; Carr AA; Krause S; Jordan R; Roniker B; Oigman W
    Am J Cardiol; 2003 Jul; 92(1):38-42. PubMed ID: 12842242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of enalapril and low-dose thiazide reduces normoalbuminuria in essential hypertension.
    Nielsen S; Dollerup J; Nielsen B; Mogensen CE
    J Hypertens; 1998 Oct; 16(10):1539-44. PubMed ID: 9814627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
    Lainscak M; Pelliccia F; Rosano G; Vitale C; Schiariti M; Greco C; Speziale G; Gaudio C
    Int J Cardiol; 2015 Dec; 200():25-9. PubMed ID: 26404748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.